百利天恒 reported revenue of ¥0.19B for the period ended 2026-06-30, +9.4% year on year. Net income was ¥-1.64B, a -874.0% net margin on a 48.1% gross margin. The largest revenue line is 药品销售收入 at 99% of the total. Free cash flow for the period was ¥-0.93B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.19B | +9.4% |
| Gross profit | ¥0.09B | — |
| Operating income | ¥-1.67B | — |
| Net income | ¥-1.64B | — |
| Gross margin | 48.1% | Net margin -874.0% |
| Revenue Q/Q | -1.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品销售收入 | ¥0.19B | 99.5% |
| 其他(补充) | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.10B | 51.9% |
| R&D | ¥1.48B | 791.5% |
| SG&A | ¥0.24B | 127.8% |
| Tax & other | ¥-0.03B | -17.0% |
| Item | Amount |
|---|---|
| Total assets | ¥11.06B |
| Total liabilities | ¥6.45B |
| Shareholders' equity | ¥4.61B |
| Equity / assets | 41.7% |
| Operating cash flow | ¥-0.79B |
| Capital expenditure | ¥0.14B |
| Free cash flow | ¥-0.93B |
| Cash conversion (OCF / net income) | 94% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
芯原股份 ・ 中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies